Salah Fares in Houston, Texas

Medical School: Sorry, his university is not listed
Graduation Year: 2000
The Primary Medical Specialty for Salah Fares is listed as: Pulmonary Disease
Approximate Years of Experience: 24
PAC (PECOS ID)#: 9032262712
NPI #: 1780850974
NPI Created On: 05/07/2008
NPI Last Updated Listed as: 09/11/2015
Primary Taxonomy Code: 207RP1001X
License Number:
Q3670
Listed Gender: Male

Forms of insurance accepted by include, but are not limited to:

• Humana
• Community Health Choice
• Celtic Insurance Company
• Blue Cross Blue Shield
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English.

Services and Procedures include:

1. Irrigation and suction of lung airways to obtain cells using an endoscope
2. Ct scan chest
3. Nuclear medicine study with ct imaging skull base to mid-thigh
4. Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration
5. Determination of lung volumes using plethysmography
6. Measurement of lung diffusing capacity
7. Injection beneath the skin or into muscle for therapy, diagnosis, or prevention
8. New patient office or other outpatient visit, typically 60 minutes
9. Established patient office or other outpatient visit, typically 5 minutes
10. Established patient office or other outpatient visit, typically 15 minutes
11. Established patient office or other outpatient, visit typically 25 minutes
12. Established patient office or other outpatient, visit typically 40 minutes
13. Initial hospital inpatient care, typically 70 minutes per day
14. Subsequent hospital inpatient care, typically 25 minutes per day
15. Subsequent hospital inpatient care, typically 35 minutes per day
16. Critical care delivery critically ill or injured patient, first 30-74 minutes
17. Smoking and tobacco use intermediate counseling, greater than 3 minutes up to 10 minutes
18. Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge
19. Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries